Clinical study of autologous hematopoietic stem cell transplantation in the treatment of patients with malignant hemopathy
10.3760/cma.j.issn.1009-9921.2010.06.014
- VernacularTitle:自体造血干细胞移植治疗恶性血液病疗效观察
- Author:
Feiheng CHEN
;
Yongzhong SU
;
Huijun LI
;
Suchun LU
;
Chunian ZHUANG
;
Yuansheng LIU
- Publication Type:Journal Article
- Keywords:
Hematologic neoplasms;
Hematopoietic stem cell transplantation;
Transplantation,autologous
- From:
Journal of Leukemia & Lymphoma
2010;19(6):360-362
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the efficacy of autologous hematopoietic stem cell transplantation (auto-AHSCT) in treatment of malignant hemopathy. Methods A retrospective study was accomplished on the auto-AHSCT in the treatment of 28 patients with malignant hemopathy from Oct 1994 to May 2009. The median age of the patients was 30 (16-45) years. Among the 28 patients,19 cases were acute myelocytic leukemia (AML),4 cases were acute lymphoblastic leukemia (ALL) and 5 cases were malignant lymphoma (ML). Mobilization of peripheral blood stem cell was recieved by giving granulocyte colony-stimulating factor (G-CSF) 5-10 μg/kg. The patients were pretreated with melphalan (140-160 mg/m2),cyclophosphamide (120 mg/kg) and arabinosylcytosin (2 g/m2). Results Transplant-related side effects was less and the hematologic recovery of most patients(26 cases) was quite rapid. The days to stable neutrophil count of 0.5×109/L and platelet count of 20×109/L were 12(8-38) d and 14(9-128) d,respectively. The median followup duration was 36(7-68) months. 19 cases (68 %) achieved disease-free survival(DFS) and 9 cases (32 %)died in three years. Of the 9 death patients,7 cases (25 %) died of recurrence and 2 cases (7 %) died of posttransplant complications. Conclusion AHSCT is a safe and effective therapy method for malignant hemopathy.
